Dr. Reddy’s Labs (RDY) Launches Generic Plavix Tabs (SNY)
Tweet
Share
E-mailGet Alerts RDY Hot Sheet
Join SI Premium – FREE
Dr. Reddy’s Laboratories (NYSE: RDY) has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of Sanofi's (NYSE: SNY) PLAVIX®, in the U.S. market on May 18, 2012. The ANDAs for Clopidogrel Tablets USP, 75 mg & 300 mg are approved by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Laboratories was among the first applicants to submit a substantially complete ANDA for Clopidogrel Tablets USP, 300 mg with a Paragraph IV certification, and was awarded 180 days of marketing exclusivity for this strength.
The PLAVIX® brand had U.S. sales of approximately $6.740 billion for the most recent twelve months ending March 2012 according to IMS Health.
Dr. Reddy’s Clopidogrel Tablets USP, 75 mg are available in bottle count sizes of 30, 90 and 500, and Clopidogrel Tablets USP, 300 mg are available in blister packs of 30's count.
The PLAVIX® brand had U.S. sales of approximately $6.740 billion for the most recent twelve months ending March 2012 according to IMS Health.
Dr. Reddy’s Clopidogrel Tablets USP, 75 mg are available in bottle count sizes of 30, 90 and 500, and Clopidogrel Tablets USP, 300 mg are available in blister packs of 30's count.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Home Depot expands executive roles, grants $500K in restricted stock
- Cytek faces $56M damages award in Beckman Coulter patent case
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
